ZA96527B - Novel pharmaceutical combination - Google Patents

Novel pharmaceutical combination

Info

Publication number
ZA96527B
ZA96527B ZA96527A ZA96527A ZA96527B ZA 96527 B ZA96527 B ZA 96527B ZA 96527 A ZA96527 A ZA 96527A ZA 96527 A ZA96527 A ZA 96527A ZA 96527 B ZA96527 B ZA 96527B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical combination
novel pharmaceutical
novel
combination
pharmaceutical
Prior art date
Application number
ZA96527A
Other languages
English (en)
Inventor
Johan Georg Harmenberg
Ann Harriet Marg Kristofferson
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of ZA96527B publication Critical patent/ZA96527B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
ZA96527A 1995-02-06 1996-01-23 Novel pharmaceutical combination ZA96527B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9500114 1995-02-06

Publications (1)

Publication Number Publication Date
ZA96527B true ZA96527B (en) 1996-08-06

Family

ID=20396821

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA96527A ZA96527B (en) 1995-02-06 1996-01-23 Novel pharmaceutical combination

Country Status (30)

Country Link
US (2) USRE39264E1 (zh)
EP (2) EP0809498B1 (zh)
JP (2) JP4260220B2 (zh)
KR (1) KR100431042B1 (zh)
CN (1) CN1131034C (zh)
AR (1) AR002030A1 (zh)
AT (2) ATE262907T1 (zh)
AU (1) AU716809B2 (zh)
CA (1) CA2211389C (zh)
DE (3) DE69632034T2 (zh)
DK (1) DK0809498T3 (zh)
DZ (1) DZ1966A1 (zh)
ES (1) ES2214528T3 (zh)
FI (1) FI119415B (zh)
FR (1) FR10C0038I2 (zh)
HK (1) HK1004368A1 (zh)
HR (1) HRP960034B1 (zh)
IL (1) IL116913A0 (zh)
MA (1) MA23800A1 (zh)
MY (1) MY119365A (zh)
NO (1) NO314220B1 (zh)
NZ (1) NZ301407A (zh)
PT (1) PT809498E (zh)
SA (1) SA96160590B1 (zh)
SI (1) SI0809498T1 (zh)
TN (1) TNSN96024A1 (zh)
TW (1) TW438585B (zh)
WO (1) WO1996024355A1 (zh)
YU (1) YU49477B (zh)
ZA (1) ZA96527B (zh)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9601544D0 (en) * 1996-01-26 1996-03-27 Smithkline Beecham Plc Pharmaceuticals
IT1287114B1 (it) * 1996-10-31 1998-08-04 Recordati Chem Pharm Composizioni farmaceutiche antierpetiche per applicatori topici, contenenti aciclovir
US7223387B2 (en) 1998-11-18 2007-05-29 Medivir Ab Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester
SE9803929D0 (sv) * 1998-11-18 1998-11-18 Medivir Ab Antiviral formulation
US7767216B2 (en) * 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
US7655252B2 (en) 1999-04-28 2010-02-02 The Regents Of The University Of Michigan Antimicrobial nanoemulsion compositions and methods
FR2837102B1 (fr) * 2002-03-18 2004-10-08 Palbian Snc Composition a l'etat de gel aqueux, procede de fabrication et utilisation pour la fabrication d'un medicament, notamment antiherpetique
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
US20050208083A1 (en) 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
EP1663999A2 (en) * 2003-08-29 2006-06-07 Ranbaxy Laboratories, Ltd. Inhibitors of phosphodiesterase type-iv
WO2005051931A2 (en) * 2003-11-26 2005-06-09 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
US7618950B2 (en) * 2004-07-07 2009-11-17 Arigen Pharmaceuticals, Inc. Method for treatment and prevention of herpes zoster by topical application
EP2394651A1 (en) * 2005-03-30 2011-12-14 Novartis AG Penciclovir or Famciclovir for the Treatment of Recurrent Genital Herpes With a One-Day Application
JP2008535918A (ja) * 2005-04-11 2008-09-04 ナノバイオ コーポレーション 感染性の症状を処置するための四級アンモニウムハライド
WO2008051186A2 (en) * 2005-08-09 2008-05-02 Nanobio Corporation Nanoemulsion containing compositions having ant i -inflammatory activity
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
US7797337B2 (en) * 2005-09-29 2010-09-14 Scenera Technologies, Llc Methods, systems, and computer program products for automatically associating data with a resource as metadata based on a characteristic of the resource
AU2006305620A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
CA2626612A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
FR2900577B1 (fr) * 2006-05-04 2008-09-12 Goemar Lab Sa Nouveaux medicaments pour les traitements contre le virus de l'herpes
EP2066661A2 (en) * 2006-09-22 2009-06-10 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
CN101616901A (zh) * 2006-09-22 2009-12-30 兰贝克赛实验室有限公司 Iv型磷酸二酯酶的抑制剂
US20080207659A1 (en) * 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
US20110130403A1 (en) * 2007-03-14 2011-06-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
CN103497185A (zh) 2007-03-14 2014-01-08 兰贝克赛实验室有限公司 用作磷酸二酯酶抑制剂的吡唑并(3,4-b)吡啶衍生物
WO2008134033A1 (en) * 2007-04-26 2008-11-06 The Trustees Of The University Of Pennsylvania Dna polymerase inhibitors composition and methods
US8747872B2 (en) 2007-05-02 2014-06-10 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
JP4972062B2 (ja) * 2008-03-17 2012-07-11 メディヴィル・アクチエボラーグ 抗ウイルス製剤
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
US20090291895A1 (en) * 2008-05-23 2009-11-26 Wong Scott W Methods and Compositions for the Treatment of Inflammatory Diseases
WO2011035120A2 (en) * 2009-09-17 2011-03-24 Gk Ventures, L.L.C. Therapeutic composition to treat lesions caused by herpes simplex virus
CN102049050B (zh) * 2009-11-02 2014-06-18 重庆华邦制药有限公司 抗疱疹病毒感染的药物组合物
EP2489354A1 (en) 2011-02-18 2012-08-22 Vironova AB Pharmaceutical formulation of B220 for topical treatment of herpes
ITMI20111747A1 (it) * 2011-09-28 2013-03-29 Fidia Farmaceutici Composizioni farmaceutiche topiche comprendenti aciclovir
FR2983731B1 (fr) * 2011-12-07 2014-04-25 Univ Paris Descartes Emulsions topiques a base de melanges eutectiques d'anesthesiques locaux et d'acide gras
TWI629062B (zh) 2013-03-13 2018-07-11 香港商安能泰製藥有限公司 含有局部麻醉劑之局部用抗病毒組合物及其製備方法
CN104324039A (zh) * 2014-10-20 2015-02-04 付茜 一种治疗人身体表面脂肪瘤的药剂及使用方法
CN108853140A (zh) * 2018-07-18 2018-11-23 豆立忠 一种多药物模块软膏及其制备方法
EP3836934B1 (en) * 2018-08-17 2023-06-21 Ilko Ilaç Sanayi Ve Ticaret Anonim Sirketi Phase stable topical composition comprising acyclovir and hydrocortisone
CA3142831A1 (en) 2019-06-14 2020-12-17 Propella Therapeutics, Inc. Topical acyclovir formulations and uses thereof
CN112569243A (zh) * 2019-09-30 2021-03-30 神农医药科技有限公司 制备治疗阿尔茨海默病的药物
EP4149443A4 (en) * 2020-05-11 2024-05-29 Revir, Inc. COMPOSITIONS AND METHODS FOR TREATING VIRUS INFECTIONS
CN112704154A (zh) * 2020-12-24 2021-04-27 中国人民解放军66399部队 一种用于治疗宠物猫疱疹病毒的营养膏
US11951082B2 (en) 2022-08-22 2024-04-09 Ford Therapeutics, Llc Composition of chlorhexidine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3317384A (en) * 1964-06-08 1967-05-02 Upjohn Co Treatment of topical viral infections with glucocorticoids and nucleosides
US4512978A (en) 1980-01-24 1985-04-23 Inwood Louis R Dermatological composition useful in the treatment of psoriasis
US4902678A (en) * 1982-02-12 1990-02-20 Syntex (U.S.A.) Inc. Anti-viral compositions
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
EP0594223B1 (en) 1985-09-17 2000-03-01 The Wellcome Foundation Limited Combination of therapeutic nucleosides and further therapeutic agents.
US4942031A (en) 1988-02-23 1990-07-17 Levin Robert H Compositions containing LYCD and other topically active medicinal ingredients
US5023090A (en) 1989-08-16 1991-06-11 Levin Robert H Topical compositions containing LYCD and other topically active medicinal ingredients for the treatment of ACNE
WO1990006775A1 (en) * 1988-12-14 1990-06-28 Liposome Technology, Inc. A novel nonphospholipid liposome composition for sustained release of drugs
AU636255B2 (en) 1990-11-05 1993-04-22 Arthropharm Pty Ltd Use of a topical formulation for the treatment of viral infections and neoplastic disorders
US5856364A (en) 1991-03-01 1999-01-05 Warner Lambert Company Therapeutic antiviral-wound healing compositions and methods for preparing and using same
ATE221379T1 (de) * 1991-05-01 2002-08-15 Jackson H M Found Military Med Verfahren zur behandlung infektiöser respiratorischer erkrankungen
IL104283A (en) * 1992-12-30 1996-12-05 Agis Ind 1983 Ltd Non-emulsion antiviral topical pharmaceutical composition comprising acyclovir an aqueous gel agent and an alkali oleate
GB9315755D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized formulation
DZ1965A1 (fr) * 1995-02-06 2002-07-17 Astra Ab Composition pharmaceutique nouvelle.
GB9601544D0 (en) 1996-01-26 1996-03-27 Smithkline Beecham Plc Pharmaceuticals

Also Published As

Publication number Publication date
DZ1966A1 (fr) 2002-10-15
JPH11506417A (ja) 1999-06-08
AU716809B2 (en) 2000-03-09
FI973243A0 (fi) 1997-08-06
KR100431042B1 (ko) 2004-06-16
HK1004368A1 (en) 1998-11-27
YU49477B (sh) 2006-05-25
US6337324B1 (en) 2002-01-08
AU4682196A (en) 1996-08-27
JP2007284452A (ja) 2007-11-01
CN1131034C (zh) 2003-12-17
USRE39264E1 (en) 2006-09-05
JP4260220B2 (ja) 2009-04-30
IL116913A0 (en) 1996-05-14
FR10C0038I1 (zh) 2010-10-15
NZ301407A (en) 1999-01-28
DE69632034D1 (de) 2004-05-06
FI973243A (fi) 1997-08-06
EP0809498B1 (en) 2004-03-31
NO314220B1 (no) 2003-02-17
NO973612D0 (no) 1997-08-05
FI119415B (fi) 2008-11-14
EP1419803A3 (en) 2004-06-09
FR10C0038I2 (zh) 2011-04-29
DE122010000032I1 (de) 2010-10-21
ATE262907T1 (de) 2004-04-15
EP0809498A1 (en) 1997-12-03
MA23800A1 (fr) 1996-10-01
PT809498E (pt) 2004-06-30
NO973612L (no) 1997-09-26
DE69632034T2 (de) 2004-10-14
CN1179718A (zh) 1998-04-22
CA2211389C (en) 2007-11-20
WO1996024355A1 (en) 1996-08-15
SI0809498T1 (en) 2004-12-31
KR19980701959A (ko) 1998-06-25
HRP960034A2 (en) 1997-10-31
TNSN96024A1 (fr) 2005-03-15
ES2214528T3 (es) 2004-09-16
AR002030A1 (es) 1998-01-07
EP1419803A2 (en) 2004-05-19
MY119365A (en) 2005-05-31
DE69637828D1 (de) 2009-03-12
TW438585B (en) 2001-06-07
ATE421358T1 (de) 2009-02-15
DK0809498T3 (da) 2004-05-10
EP1419803B1 (en) 2009-01-21
YU7296A (sh) 1998-08-14
SA96160590B1 (ar) 2005-10-05
CA2211389A1 (en) 1996-08-15
HRP960034B1 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
IL116913A0 (en) Novel pharmaceutical combination
HU9601698D0 (en) Pharmaceutical composition
EP0850057A4 (en) PHARMACEUTICAL COMPOSITIONS
GB9519667D0 (en) Pharmaceutical composition
ZA962214B (en) Pharmaceutical composition
ZA963590B (en) Pharmaceutical composition
GB9525194D0 (en) Pharmaceutical composition
GB9502695D0 (en) Pharmaceutical composition
ZA964193B (en) Pharmaceutical composition
AP9801196A0 (en) Pharmaceutical preparation
HU9603498D0 (en) Pharmaceutical compounds
HU9602822D0 (en) Pharmaceutical composition
ZA963591B (en) Pharmaceutical composition
ZA95736B (en) Pharmaceutical composition
GB9521970D0 (en) Novel pharmaceutical
GB9521918D0 (en) Novel pharmaceutical
GB9502542D0 (en) Novel pharmaceutical use
GB9405248D0 (en) Novel pharmaceutical
GB9516710D0 (en) Medicine
GB9507678D0 (en) Pharmaceutical mixtures
GB9507037D0 (en) Pharmaceutical composition
GB9515207D0 (en) Pharmaceutical composition
ZA961735B (en) Pharmaceutical composition
HU9903430D0 (en) Pharmaceutical composition
GB9519748D0 (en) Pharmaceutical composition